ClinicalTrials.gg
CompletedNCT02376049Updated Feb 24, 2025

A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)

A Phase 1 interventional study of Pimecrolimus cream and Betamethasone dipropionate cream in Atopic Dermatitis, sponsored by LEO Pharma. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by LEO Pharma · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing pimecrolimus in Dermatitis, Atopic — none open to participants now, none under way, none of them phase 3. pimecrolimus · Dermatitis, Atopic.

Enrollment
20th of 24
30 · median 113
Started
2015
the only one that year
Phase 1
2 of 27
none open now
Registered
24th of 27
by date
Lead sponsor
2 of 27
LEO Pharma

Among the 27 studies testing pimecrolimus in Dermatitis, Atopic, this one is the 20th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2015, is one of 2 in phase 1, and was the 24th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 27 studies testing pimecrolimus in Dermatitis, Atopic is open now. The open studies under Dermatitis, Atopic, anywhere →

About pimecrolimus

pimecrolimus: first FDA approval 2001 (ELIDEL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies testing pimecrolimus in Dermatitis, Atopic as a file.
02

Study summary

An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical Agents in Adults with Mild to Moderate Atopic Dermatitis.

Read the detailed description

Multi-center, prospective, randomized, vehicle-controlled, investigator-blinded, stable lesion design.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Atopic Dermatitis
  • Eczema
  • AD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject with mild to moderate AD
  • Four comparable TAs
  • TSS of at least 5 on all TAs
  • Difference in TSS not greater than 2 between the TAs
  • Sign score erythema ≥ 2 between the TAs
  • TAs should be at least 2 cm apart

Exclusion criteria

Exclusion Criteria:

  • Investigator's opinion
  • Fitzpatrick skin type >5
  • Topical (i.e. on the TAs) treatment with prohibited medications
  • Systemic treatment with prohibited medications
  • Phototherapy within prohibited timeframe
  • Use of emollients within prohibited timeframe
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Pimecrolimus cream

    Pimecrolimus 1% cream once daily for 14 days

    Drug: Pimecrolimus cream

  • Active comparator
    Betamethasone dipropionate cream

    Betamethasone dipropionate 0.05% cream once daily for 14 days

    Drug: Betamethasone dipropionate cream

  • Active comparator
    Clobetasol propionate cream

    Clobetasol propionate 0.05% cream once daily for 14 days

    Drug: Clobetasol propionate cream

  • Placebo comparator
    Glaxal Base cream vehicle

    Glaxal Base cream vehicle once daily for 14 days

    Drug: Glaxal Base cream vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Total Sign Score (TSS) change

    TSS change at end of treatment in relation to baseline

    Time frame: 14 days

07

Study locations

2 sites
  • Innovaderm Research Inc.
    Montreal, Quebec H2K 4L5, Canada
  • Beit Harofim
    Netanya, 42701, Israel
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2015
First posted
Mar 3, 2015
Start
Feb 2015
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02376049
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Mar 3, 2015
Start date
Feb 2015
Primary completion
Jul 2015
Completion
Jul 2015
Last update
Feb 24, 2025

Study contacts

Emma Guttmann, MD
principal investigator · Icahn School of Medicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pimecrolimus · Betamethasone dipropionate · Clobetasol

Start the discussion